Antileishmanial treatment using chemotherapy in combination with immunomodulators in experimental Visceral Leishmaniasis
IR@CDRI: CSIR-Central Drug Research Institute, Lucknow
View Archive Info| Field | Value | |
| Creator |
Sane, Shraddha A.
|
|
| Date |
2014-05-27T10:29:05Z
2014-05-27T10:29:05Z 2010 |
|
| Identifier |
http://hdl.handle.net/123456789/1260
|
|
| Description |
Guide- Dr. Suman Gupta, PhD. Thesis Submitted to JNU, New Delhi in 2010.
Leishmaniases, in its variety of visceral (VL), cutaneous (CL) and mucocutaneous (MCL) forms, directly affects about 2 million people per annum, with approximately 350 million individuals at risk worldwide. During the last 10 years there have been extensive epidemics of visceral form of the disease, which is also emerging as an important opportunistic infection in immunocompromised patients, especially those co-infected with HIV. No vaccines exist for VL, CL or MCL and chemotherapy is inadequate and expensive. In the present scenario drug combinations have proven to be an essential feature of antimicrobial treatment through design or use, to (i) increase activity through use of compounds with synergistic or additive activity, (ii) prevent the emergence of drug resistance, (iii) lower required doses, reducing chances of toxic side effects and cost, (iv) increase the spectrum of activity. The work of the present Ph.D. thesis has been divided in to six chapters. Each chapter deals with a specific objective. The 1st chapter provides general information regarding Leishmaniasis and its parasite, history, taxonomy, global surveillance, epidemiology, life cycle, vector and transmission. The 2nd chapter deals with an exploratory review on conventional therapy for VL, molecular mechanism involve in parasite invasion and host immune response during leishmaniasis. Chapter 3rd gives detail information regarding the application of combination therapy for treatment of the disease. The 4th chapter provides detail description of materials and methods used during study. The 5th chapter describes combination therapy using immunomodulator CpG oligodeoxynucleotides with miltefosine in L.donovani/hamster and BALB/c mouse model. The 6th chapter explains combination therapy using immunomodulator and hepatoprotective agent picroliv with paromomycin and miltefosine in L.donovani/hamster model. |
|
| Format |
3440618 bytes
application/pdf |
|
| Language |
en
|
|
| Relation |
CSIR-CDRI Thesis No. - S-250
|
|
| Subject |
Antileishmanial
Chemotherapy Immunomodulators Visceral Leishmaniasis |
|
| Title |
Antileishmanial treatment using chemotherapy in combination with immunomodulators in experimental Visceral Leishmaniasis
|
|
| Type |
Thesis
|
|